FIT Biotech Oy said the US Patent and Trademark Office issued a patent titled “Methods of treating HIV diseases using novel expression vectors.”
The patent grants FIT Biotech exclusive rights to exploit its GTU-based DNA vaccines, including FIT-06, for the treatment of HIV patients.
“The company’s clinical stage candidate FIT-06 aims to address the problems of standard therapies including restricted access to medication, low patient retention in therapy, social stigma and potentially serious side effects,” said FIT Biotech.
Santeri Kiviluoto, Chief Scientific Officer of FIT Biotech Oy, said: “Having patent protection for FIT-06 is of utmost importance since it provides FIT exclusive rights for commercializing the vaccine candidate.
“The upcoming Phase 2 clinical trial with the European HIV Alliance (EHVA) will be the next step on this journey and we look very much forward to its start.”